spacer
home > ebr > Spring 2006
PUBLICATIONS

European Biopharmaceutical Review

ebr
Spring 2006
At the cutting edge of the latest industry developments, Samedan is adept at keeping the information you need at your fingertips. EBR provides a unique platform of communication for the market across Europe, North America and the rest of the developed world. To find out what's hot in the world of of biopharmaceuticals, take a look below at the range of articles featured in this issue of EBR
   
Text
PDF
Helen Tayton-Martin, EBR's Editor, casts an eye over the spring issue  
download pdf
bullet
BioFinance and Management
In offering a myriad of benefits to both universities and the public, spinouts are attracting government support, but long-term financing options are nevertheless a challenge. Dr Jonathan Savidge at UCL Biomedica considers approaches to funding, in Reeling in Returns from Biotech Spinouts  
download pdf
In Aiming for Success, Ian Dixon at PricewaterhouseCoopers LLP looks at the popularity of the AIM market, whose rate of new admissions now surpasses that of the LSE's main market  
download pdf
Funding remains a major concern for biotech, and investor attitudes are tempered with caution, but an air of optimism is emerging. Hanns-Peter Wiese at Global Life Science Ventures considers whether fortunes are shifting, in After the Hype: The Horizons for Biotech  
download pdf
bullet
BioBusiness Development
In Spinning Out of Constraints, Dr Catherine Beech at Cambridge Gateway Fund and Dr John Mihell at Warwick Ventures, define key factors that promote or limit the rate of spinout formation at UK universities  
download pdf
Joanne Pearson at PharmaVentures looks at the scientific, social and commercial advantages of R&D agreements, in Strength in Synergy  
download pdf
Alongside management, IP has been posited as a primary consideration in evaluating the prospects of life sciences technologies. Dana M Gordon at Foley Hoag LLP examines the importance of well-informed IP strategies in Proof of Purpose: The US Utility Requirement  
download pdf
Nicos Nicolaou at the Tanaka Business School, Imperial College London, explores the relationship between Institutional Structures and the Creation of University Spinouts  
download pdf
bullet
BioResearch and Innovation
Roger A Edwards, ScD, Donna Mayo, Sharon Els and Louis Kaczmarek of PA Consulting predict the potential success of emergency measures in Avian Flu А Pandemic Prevention  
download pdf
Drugs able to target multiple gene products and curb the formation of resistant tumour cells would extend the effectiveness of existing treatments, says Rudolf Fahrig of RESprotect GmbH, in Combating Chemoresistance А Chemogenomics Joins the Battleground  
download pdf
There are currently over 80 clinical trials of therapies directed against tumour blood vessels. Dietmar W Siemann at the Department of Radiation Oncology, University of Florida Shands Cancer Center, uncovers their potential, in Strength in Numbers: Pairing Vascular Anticancer Therapies  
download pdf
In Innovation for Regeneration, Dr Carola Dony at Scil Technology GmbH explores the history and future of therapies for cartilage defects  
download pdf
Cristina Serra at EVGN evaluates developments in the treatment of cardiovascular disease in When Body Plumbers turn into Molecular Experts  
download pdf
bullet
Discovery Technology
In Design and Optimise: The Art of RNA Interference, Maureen Young and Dmitriy Ovcharenko of Ambion Inc explore this powerful reverse genetics tool that has revolutionised the study of gene function  
download pdf
Debra Nickischer at Cellomics and Anja van Brabant Smith at Dharmacon detail the compatibility of RNAi and the HCS platform for the functional mapping of genes, in High Content Analysis Using Targeted RNAi-Mediated Gene Knockdown  
download pdf
In RNAi: The Silent System, Subrahmanyam Yerramilli and Eric Lader at QIAGEN Sciences, US, and Elizabeth Scanlan at QIAGEN GmbH, Germany, discuss the multiple applications of RNA interference  
download pdf
bullet
BioDevelopment and Regulatory
With the average cost of drug development now peaking at a massive $1.7 billion, the pressure on companies to generate revenue is greater than ever. Faiz Kermani at Chiltern looks at the specific hurdles involved and strategies to overcome them, in Risk Evasion: The Challenges Ahead  
download pdf
In The Human Factor, Neil Sullivan at Cord8 Ltd unravels complexities in the interpretation of the Human Tissue Act 2004, and asks whether it enhances previous legislation on the removal, storage and use of human organs and tissue  
download pdf
Philippe Stas, Dr Ivo van Walle and Dr Ignace Lasters at AlgoNomics tackle a thorn-in-the-side of biopharmaceutical development, in T-Cell Epitopes: Predicting Immunogenicity  
download pdf
Dr Graham Lappin and Professor Colin Garner at Xceleron Ltd explore Absolute Bioavailability Studies in Humans - the Merits of Accelerator Mass Spectrometry  
bullet
BioFormulation and Manufacturing
In Biopharmaceutical Sialylation, Dr Daryl L Fernandes at Ludger Ltd presents a guide to assembling a glycoprofiling scheme for characterisation of biopharmaceutical sialylation  
download pdf
Cold chain management goes under the spotlight in Trial Run by Dan Catizone of QuickSTAT  
download pdf
Dr Bettina Katterle, Kerstin Mяller and Melanie Dippel at NewLab BioQuality AG underline the importance of validated stability testing methods for biopharmaceuticals  
download pdf
In The Bioreactor Maze, Richard Dennett at Eden Biodesign clarifies the considerations to be made when selecting this key component of the production process  
download pdf
Claudia Petersen and Fran DeGrazio at West Pharmaceuticals investigate the problem of product/container interactions in Packaging Creation: Risk Mitigation  
download pdf
bullet
BioRegional
In Poised for Growth: Chicago's Solo Turn, Arun Bhatia at The University of Chicago Graduate School of Business provides an overview of the life sciences in the city hosting this year's BIO conference  
download pdf
bullet
Preview
A look ahead to SCIpharm 2006 - Where Science Meets Business  
download pdf
   
spacer
Edited by
Dr Deborah O'Neil,
Chief Executive and Scientific Officer,
NovaBiotics Ltd
Published quarterly in
January, April,
July and October

News and Press Releases

PCI Clinical Services Welcomes Marc Rees to its International Clinical Sales Team

Leading outsourcing services provider PCI Clinical Services has announced the appointment of Marc Rees in the role of Business Development Manager responsible for UK and Ireland.
More info >>

White Papers

Detecting Integrity Breaches in a range of Pharmaceutical Blister Package Types using Sepha VisionScan

Sepha Limited

Demonstrating the integrity of pharmaceutical blister packs is critically important, as any defects can affect the shelf life and efficacy of the contents. Compared to bulk packaging, blister packs offer improved product integrity, tamper evidence and reduce the likelihood of misuse. Packs can be composed of either a thermoformed polymer or cold formed aluminium tray, with a number of individual pockets to hold the product. After the tablets or capsules are placed in the pockets, the packs are heat sealed with a paper or foil laminate sheet. These various stages can be completed separately or integrated into a single form, fill and seal process. There is a risk of microbial containment or degradation of the contents if any defects are present in the packaging. Such defects can take the form of rips or pinholes in the tray, or lid materials, faulty seals and channel leaks between pockets.
More info >>

Industry Events

Pharmaceutical Microbiology East Coast

13-14 November 2017, Renaissance Woodbridge Hotel, New Jersey

Drawing on from the huge success of SMiís Pharmaceutical Microbiology event series, SMi is delighted to announce the launch of Pharmaceutical Microbiology East Coast. Being the eighth in its series, this event will take place in New Jersey, USA, on November 13th and 14th 2017. Aimed at Microbiologists, Quality Control and Quality Assurance Managers, Pharmaceutical Microbiology East Coast 2017 will address the best practices for rapid microbial and sterility testing and tackle the challenges of contamination control.
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement